FRAT1 anticorps (AA 161-260) (Cy7)

N° du produit ABIN1708428

Détail du produit anti-FRAT1 anticorps (Cy7)

Antigène: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Épitope: AA 161-260

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FRAT1 est conjugé à/à la Cy7

Application: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat,Dog,Cow

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human FRAT1

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur FRAT1

Antigène: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Autre désignation: FRAT1 (FRAT1 Produits)

Synonymes: anticorps FRAT1, anticorps frat1, anticorps AW060382, anticorps gbp, anticorps FRAT1, WNT signaling pathway regulator, anticorps GSK-3 binding protein FRAT1, anticorps frequently rearranged in advanced T cell lymphomas, anticorps frequently rearranged in advanced T-cell lymphomas, anticorps frequently rearranged in advanced T-cell lymphomas 1 S homeolog, anticorps FRAT1, anticorps frat1, anticorps Frat1, anticorps frat1.S

Sujet:

Synonyms: FRAT 1, frequently rearranged in advanced T cell lymphomas, Frequently rearranged in advanced T-cell lymphomas, GSK 3 binding protein FRAT1, proto oncogene FRAT1, FRAT1_HUMAN.

Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

ID gène: 10023